PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.35%
Cash & equivalents declining -35.35% while AXSM's grows 404.03%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-35.35%
Below half of AXSM's 404.03%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.32%
Higher Other Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-30.67%
Below half of AXSM's 398.19%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-13.90%
1.25-1.5x AXSM's -11.38%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Less than half of AXSM's -17.22%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-10.42%
0.5-0.75x AXSM's -16.23%. Martin Whitman wonders if there's insufficient reinvestment vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
Below half of AXSM's 396.29%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-10.38%
Less than half of AXSM's 15.83%. David Dodd sees a more disciplined AP approach or lower volume.
1404.09%
Above 1.5x AXSM's 301.26%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
10.38%
Below half of AXSM's 34.71%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
-3.56%
Less than half of AXSM's 32.34%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.88%
Above 1.5x AXSM's -9.29%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-5.58%
Less than half of AXSM's 11.19%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Below half AXSM's -16.42%. Michael Burry suspects major net losses or high dividends vs. competitor.
-5.49%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-43.19%
Below half AXSM's -2678.13%. Michael Burry sees potential underperformance in building shareholder capital.
-28.48%
Below half AXSM's -401.69%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
14.13%
Above 1.5x AXSM's 0.90%. Michael Burry sees a major jump. Investigate leverage rationale.
40.09%
Less than half of AXSM's -737.47%. David Dodd sees better deleveraging or stronger cash buildup than competitor.